Impact of Immunocompromise on Survival in HPV-Positive Throat Cancer Patients

Introduction

Human Papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) has become increasingly common, particularly in the head and neck region. This cancer type is often linked to HPV infections and generally carries a better prognosis than HPV-negative variants. However, co-morbid conditions like immunocompromise—resulting from diseases such as HIV, leukemia, or immunosuppressive therapies—can complicate treatment and outcomes. Immunocompromise impairs the body’s ability to fight cancer and infections, potentially worsening survival rates. This study aims to characterize how immunocompromised status influences survival and morbidity in patients with surgically resected HPV-positive OPSCC, filling a gap in current research where such co-morbidities are understudied despite their clinical relevance. Understanding these associations could lead to better-targeted therapies and improved patient care protocols for this vulnerable group.

Study Methods